Spontaneous fracture of femur in patient with long-term bisphosphonates treatment
Keywords:
bisphosphonates, spontaneous fractures, Alendronate.Abstract
67-Year-old woman who suffers diaphyseal fracture of the femur, with the history of intake of bisphosphonates for several years for its osteoporosis treatment. In the literature since relatively recently are articles describing spontaneous fractures associated with patients treated with biphosfonatos for several consecutive years (1, 2), a mechanism is not clear. These drugs lower the osteoclastic activity in bone metabolism, decreasing bone turnover and increasing mineral density, but raised the theory that the removal of bone turnover may be exaggerated and predispose to fractures. Despite the partnerships established in many studies, these continue to be circumstantial, it is required to continue with the investigations and case reports to arrive at a definitive conclusion.References
1. Sayed-Noor AS, Sjödén GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009 Jul; 467(7):1921-6. Epub 2009 Feb 6.
2. Agarwal S, Agarwal PK, Agarwal G, Bansal A. Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates): a systemic review of literature. Acta Orthop Belg. 2010 Oct; 76(5):567-71.
3. Pasala S, Burshell A, Ogden F. Long-term Alendronate Therapy and Subtrochanteric Femoral Fractures. Ochsner J. 2010 Spring; 10(1): 22. Academic Division of Ochsner Clinic Foundation. Published online 2010.
4. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008 Aug; 93(8):2948-52. Epub 2008 Jun 3.
5. Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case Reports: Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy. Clin Orthop Relat Res. 2010 July; 468(7): 1991-1996. Published online 2009 December 18.
6. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009 Apr-Jun; 8(2):96-110. (Encontrado en Pubmed en abril/11).
7. Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009 Oct; 24(10):1736-40.
8. Aguilera C, Agustí A, Bosch M, Danés I, Llop R. Bifosfonatos: Una relación riesgobeneficio dudosa. Butlllety groc. 2009 junsept; 22(3).
9. Bamrungsong T, Pongchaiyakul C. Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. J Med Assoc Thai. 2010 May; 93(5):620-4.
10. Lee JK. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. Int J Rheum Dis. 2009 Jul; 12(2):149-54.
11. Pozzo MJ, Lozano MP, Mondello E. Fractura por insuficiencia de sacro en paciente bajo tratamiento con alendronato. www.aaomm.org.ar/?s=servicios_pro& sub=casos_clinicos&id=6. (encontrado el 08 febrero 2011)
12. Edwards MH, McCrae FC, Young-Min SA. Alendronate-related femoral diaphysis fracture- ¿what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int. 2010 Apr; 21(4): 701-3. Epub 2009 Jun 27.
13. Spivacow FR, Sarli M, Buttazzoni M, Tratamiento con bisfosfonatos y fracturas atípicas. Medicina (B. Aires) v.69 n.6 Ciudad Autónoma de Buenos Aires nov/dic. 2009. Versión On-line ISSN 1669-91060 (Encontrada el 8 febrero 2011).
14. Black DM, Kelly MP, Genant HK, Palermo L, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010 May 13; 362(19):1761-71. Epub 2010 Mar 24.
15. Czewinski E. Atypical subtrochanteric fractures after long-term bifosfonatos therapy. Polish Journal of endocrinology. 2011; 62 (1): 84-87.
16. Leung F, Lau TW, To M, Luk KD, Kung AW. Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Rep. 2009; 2009. pii: bcr 10.2008.1073. Epub 2009 Mar 5.
17. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009 Jun; 24(6):1095-102.
18. Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. [JOURNAL ARTICLE] Bone 2010 Dec 30.(Encontrado en Medline en marzo/11).
19. Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. [JOURNAL ARTICLE] Osteoporos Int 2010 Dec 17. (Encontrado en Medline en marzo/ 11).
20. Burr DB, Diab T, Koivunemi A, Koivunemi M, Allen MR. Effects of 1 to 3 years’ treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res. 2009 Oct; 27(10):1288-92.
21. Somford MP, Geurts GFA, Teuling JWAM, Thomassen BJW, Draijer WF. Long Term Alendronato use not whitout consequences?. Int J Reumatol. 2009; 2009: 253432. Published online 2010, January 27.
22. Schneider JP. Bisphosphonates and lowimpact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics. 2009 Jan; 64(1):18-23.
23. Abrahamsen B. Efectos adversos de los bifosfonatos (Artículo de revisión). Revista del climaterio. 2010; 14 (79): 1-19. www. nietoeditores.com.mx/download/climaterio/ noviembre-diciembre2010/Climaterio% 2079.2. (Encontrado 26 feb/11)
24. Cummings S. Aspectos Clínicos de la Osteoporosis: Actualización. Medwave. Año IX, No. 4, Abril 2009. www.mednet.cl/ link.cgi/Medwave/Congresos/3854 (encontrado 26 febrero 2011).
25. Aspenberg P, Schilcher J, Fahlgren Anna. Histology of an undisplaced femoral fatigue fractura in association with bisphosphonate treatment. Acta Orthop, 2010 August; 81 (4): 460-462. Published online 2010 July 16.
26. Girgis CM, Seibel MJ, Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures, Bone (2011), doi:10.1016/ j.bone.2011.02.013.
2. Agarwal S, Agarwal PK, Agarwal G, Bansal A. Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates): a systemic review of literature. Acta Orthop Belg. 2010 Oct; 76(5):567-71.
3. Pasala S, Burshell A, Ogden F. Long-term Alendronate Therapy and Subtrochanteric Femoral Fractures. Ochsner J. 2010 Spring; 10(1): 22. Academic Division of Ochsner Clinic Foundation. Published online 2010.
4. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008 Aug; 93(8):2948-52. Epub 2008 Jun 3.
5. Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case Reports: Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy. Clin Orthop Relat Res. 2010 July; 468(7): 1991-1996. Published online 2009 December 18.
6. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009 Apr-Jun; 8(2):96-110. (Encontrado en Pubmed en abril/11).
7. Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009 Oct; 24(10):1736-40.
8. Aguilera C, Agustí A, Bosch M, Danés I, Llop R. Bifosfonatos: Una relación riesgobeneficio dudosa. Butlllety groc. 2009 junsept; 22(3).
9. Bamrungsong T, Pongchaiyakul C. Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. J Med Assoc Thai. 2010 May; 93(5):620-4.
10. Lee JK. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. Int J Rheum Dis. 2009 Jul; 12(2):149-54.
11. Pozzo MJ, Lozano MP, Mondello E. Fractura por insuficiencia de sacro en paciente bajo tratamiento con alendronato. www.aaomm.org.ar/?s=servicios_pro& sub=casos_clinicos&id=6. (encontrado el 08 febrero 2011)
12. Edwards MH, McCrae FC, Young-Min SA. Alendronate-related femoral diaphysis fracture- ¿what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int. 2010 Apr; 21(4): 701-3. Epub 2009 Jun 27.
13. Spivacow FR, Sarli M, Buttazzoni M, Tratamiento con bisfosfonatos y fracturas atípicas. Medicina (B. Aires) v.69 n.6 Ciudad Autónoma de Buenos Aires nov/dic. 2009. Versión On-line ISSN 1669-91060 (Encontrada el 8 febrero 2011).
14. Black DM, Kelly MP, Genant HK, Palermo L, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010 May 13; 362(19):1761-71. Epub 2010 Mar 24.
15. Czewinski E. Atypical subtrochanteric fractures after long-term bifosfonatos therapy. Polish Journal of endocrinology. 2011; 62 (1): 84-87.
16. Leung F, Lau TW, To M, Luk KD, Kung AW. Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Rep. 2009; 2009. pii: bcr 10.2008.1073. Epub 2009 Mar 5.
17. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009 Jun; 24(6):1095-102.
18. Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. [JOURNAL ARTICLE] Bone 2010 Dec 30.(Encontrado en Medline en marzo/11).
19. Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. [JOURNAL ARTICLE] Osteoporos Int 2010 Dec 17. (Encontrado en Medline en marzo/ 11).
20. Burr DB, Diab T, Koivunemi A, Koivunemi M, Allen MR. Effects of 1 to 3 years’ treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res. 2009 Oct; 27(10):1288-92.
21. Somford MP, Geurts GFA, Teuling JWAM, Thomassen BJW, Draijer WF. Long Term Alendronato use not whitout consequences?. Int J Reumatol. 2009; 2009: 253432. Published online 2010, January 27.
22. Schneider JP. Bisphosphonates and lowimpact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics. 2009 Jan; 64(1):18-23.
23. Abrahamsen B. Efectos adversos de los bifosfonatos (Artículo de revisión). Revista del climaterio. 2010; 14 (79): 1-19. www. nietoeditores.com.mx/download/climaterio/ noviembre-diciembre2010/Climaterio% 2079.2. (Encontrado 26 feb/11)
24. Cummings S. Aspectos Clínicos de la Osteoporosis: Actualización. Medwave. Año IX, No. 4, Abril 2009. www.mednet.cl/ link.cgi/Medwave/Congresos/3854 (encontrado 26 febrero 2011).
25. Aspenberg P, Schilcher J, Fahlgren Anna. Histology of an undisplaced femoral fatigue fractura in association with bisphosphonate treatment. Acta Orthop, 2010 August; 81 (4): 460-462. Published online 2010 July 16.
26. Girgis CM, Seibel MJ, Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures, Bone (2011), doi:10.1016/ j.bone.2011.02.013.
How to Cite
1.
Gómez Rendón JF. Spontaneous fracture of femur in patient with long-term bisphosphonates treatment. Rev. Colomb. Med. Fis. Rehabil. [Internet]. 2012 Apr. 14 [cited 2024 May 19];21(2):126-30. Available from: https://revistacmfr.org/index.php/rcmfr/article/view/17
Downloads
Download data is not yet available.
